News

Mauna Kea Technologies: release of the 2022 Universal Registration Document

30 June 2023

Paris and Boston, June 30, 2023 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that it has made available to the public and filed with the Autorité des marchés financiers its Universal Registration Document for the year ending December 31, 2022. 

Mauna Kea Technologies' Universal Registration Document notably includes: 

– The 2022 financial report, comprising the consolidated financial statements, the annual financial statements and the related statutory auditors' reports; 

– The management report; 

– The corporate governance report. 

The Universal Registration Document is available on the Mauna Kea Technologies website, https://www.maunakeatech.com/fr/, in the Investors / Financial Documents section, as well as on the AMF website (www.amf-france.org). 

Latest News

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024

Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances

Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances

Mauna Kea Technologies Reports New Evidence Highly Supportive of the Use of Cellvizio for Diagnosing Pancreatic Cysts Presented at DDW 2024

Mauna Kea Technologies Reports New Evidence Highly Supportive of the Use of Cellvizio for Diagnosing Pancreatic Cysts Presented at DDW 2024